GlassScriptPhysician profile
Adam Scott Barron
NPI 1013937671
$5,363.79
in general payments reported to CMS, 2019-2025
46 companies · $1,816 in 2025
The $1,816 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $81.62 · 2021: $518 · 2022: $509 · 2023: $516 · 2024: $1,550 · 2025: $1,816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,852 · Education: $30.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,852.06 |
| Education | $30.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,105.21 | 2021-2025 | Rinvoq |
| Amgen INC. | $893.57 | 2019-2025 | Evenity, Tavneos, Tepezza |
| Novo Nordisk INC | $269.83 | 2022-2024 | Ozempic |
| Pfizer INC. | $252.45 | 2019-2025 | |
| Ucb, INC. | $246.03 | 2021-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $240.81 | 2021-2023 | Tremfya |
| Abbott Laboratories | $174.23 | 2023-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $166.82 | 2023-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $166.76 | 2025 | Saphnelo |
| Glaxosmithkline, LLC. | $158.78 | 2024-2025 | Benlysta |
| Beta Bionics, INC. | $149.41 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Mallinckrodt Hospital Products INC. | $130.70 | 2020-2025 | Acthar |
| Lilly USA, LLC | $123.47 | 2019-2025 | Taltz, Zepbound |
| Ascendis Pharma Endocrinology INC | $121.85 | 2025 | Yorvipath |
| Mallinckrodt Enterprises LLC | $105.82 | 2019 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Barron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.